Brian Lehmann
Last active: 9/15/2015

  1. Attenuation of myocardial injury in mice with functional deletion of the circadian rhythm gene mPer2. Virag JA, Dries JL, Easton PR, Friesland AM, DeAntonio JH, Chintalgattu V, Cozzi E, Lehmann BD, Ding JM, Lust RM (2010) Am J Physiol Heart Circ Physiol 298(3): H1088-95
    › Primary publication · 20061537 (PubMed) · PMC2838551 (PubMed Central)
  2. Targeting prostate cancer based on signal transduction and cell cycle pathways. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA (2008) Cell Cycle 7(12): 1745-62
    › Primary publication · 18594202 (PubMed) · PMC2593475 (PubMed Central)
  3. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA (2008) Oncogene 27(29): 4086-95
    › Primary publication · 18332865 (PubMed) · PMC3836277 (PubMed Central)
  4. Senescence-associated exosome release from human prostate cancer cells. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM (2008) Cancer Res 68(19): 7864-71
    › Primary publication · 18829542 (PubMed) · PMC3845029 (PubMed Central)
  5. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM (2008) Cell Cycle 7(9): 1262-8
    › Primary publication · 18418057 (PubMed) · PMC3474322 (PubMed Central)
  6. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, Tafuri A, Milella M, Zarzycki M, Dzugaj A, Chiarini F, Evangelisti C, Martelli AM, Terrian DM, Franklin RA, Steelman LS (2008) Adv Enzyme Regul : 113-35
    › Primary publication · 18423407 (PubMed) · PMC2583357 (PubMed Central)
  7. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM (2007) Adv Enzyme Regul : 64-103
    › Primary publication · 17382374 (PubMed) · PMC2696319 (PubMed Central)
  8. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Biochim Biophys Acta 1773(8): 1263-84
    › Primary publication · 17126425 (PubMed) · PMC2696318 (PubMed Central)
  9. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Lehmann BD, McCubrey JA, Terrian DM (2007) Cancer Biol Ther 6(8): 1165-70
    › Primary publication · 18059157 (PubMed) · PMC2889025 (PubMed Central)
  10. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM (2007) Cell Cycle 6(5): 595-605
    › Primary publication · 17351335 (PubMed)